



2027 DSCSA Update

THE DRUG SUPPLY CHAIN SECURITY ACT (DSCSA): NEW DEADLINES, REQUIREMENTS AND THE INDUSTRY IMPACT

NEW DEADLINE

FDA has extended the exemption for small dispensers by one year while it assesses their ability to trace electronically. The exemption now ends:

November 27, 2027

Small Dispensers (25 or Fewer Full-Time Pharmacists and Pharmacy Technicians)

ALREADY IN EFFECT

May 27, 2025	Manufacturers and Repackagers
August 27, 2025	Wholesale Distributors
November 27, 2025	Dispensers with 26 or More Full-Time Employees



KEY TIPS



Start Early

Starting early ensures enough time to configure, test and troubleshoot systems before the deadline.

Engage with Partners


Coordinating with supply chain partners is essential for smooth shared data practices across all stakeholder connections.

Select Reliable Solutions

Solutions like Movilitas.Cloud simplify DSCSA compliance by offering an easy-to-use platform with real-time tracking.

NON-COMPLIANCE CONSEQUENCES


Failure to comply with DSCSA requirements can result in:



Large fines



License suspension



Limited ability to operate within the supply chain

YOUR DSCSA CHECKLIST

Ensure your organization is fully prepared for DSCSA compliance with this comprehensive readiness checklist!

1

Have you finalized your integration strategy for DSCSA reporting to downstream trading partners and customers?

2

Have you assessed the impact of DSCSA full traceability on your day-to-day business operations?

3

Have you validated the performance of integrated systems that support critical business operations like serialized warehouse operations?

4

Is your serialization and events repository tightly integrated with supply chain processes and systems to ensure real-time synchronization?

5

Can your systems support DSCSA compliance with expected data volumes from 2027 onward, and is an archiving strategy in place?

6

Have you defined processes for verification requests from partners or agencies, and can your systems efficiently support investigations?

7

Are processes and systems in place to efficiently handle non-serialized, serialized and aggregated products simultaneously?

8

Have you defined processes to investigate suspect products, remove illegitimate ones from the supply chain and notify relevant parties?

9

Have you identified the processes to validate all authorized trading partners?

10

Are systems in place to properly handle exceptions?